CA
VYGR icon

Clearstead Advisors’s Voyager Therapeutics VYGR Stock Holding History

Clearstead Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25
Closed -$194 – 1612
2023
Q3 		$194 Hold
25
– – ﹤0.01% 1444
2023
Q2 		$287 Buy
+25
New +$259 ﹤0.01% 1330

Other funds holding VYGR

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Clearstead Advisors's VYGR Position: Q4 2023 in Review

Clearstead Advisors sold out of Voyager Therapeutics (VYGR) in Q4 2023, closing a stake of 25 shares — an estimated $194 sold.

Clearstead Advisors first reported a position in VYGR in Q2 2023 and held it in 2 quarters. The position peaked at $287 in Q2 2023. 107 funds tracked by Wall St. Rank hold VYGR as of Q4 2023.

  • Clearstead Advisors reported no remaining Voyager Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Clearstead Advisors sold 25 Voyager Therapeutics shares in Q4 2023, an estimated $194.
  • Clearstead Advisors first reported a position in Voyager Therapeutics in Q2 2023 and held it in 2 quarters.
  • Clearstead Advisors's Voyager Therapeutics position peaked at $287 in Q2 2023.
  • 107 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2023.

Based on Clearstead Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.